Smith & Nephew (SNN) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Smith & Nephew (SNN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

23.91

-0.11 (-0.46%)

At close: Jan 14, 2025, 3:59 PM

24.14

0.98%

Pre-market Jan 15, 2025, 06:41 AM EST

undefined% (undefined)

Bid	24.14
Market Cap	10.42B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.7
PE Ratio (ttm)	34.15
Forward PE	n/a
Analyst	Buy

Ask	24.16
Volume	718,535
Avg. Volume (20D)	890,857
Open	23.91
Previous Close	24.02
Day's Range	23.69 - 23.98
52-Week Range	23.65 - 31.72
Beta	undefined

About SNN

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint re...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Nov 16, 1999

Employees 18,000

Stock Exchange NYSE

Ticker Symbol SNN

Website https://www.smith-nephew.com

Analyst Forecast

According to 1 analyst ratings, the average rating for SNN stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

6 months ago · Source

Smith & Nephew shares are trading higher after a F... Unlock content with Pro Subscription

News

3 weeks ago · zacks.com

SNN Stock May Gain on CORIOGRAPH Platform's FDA Clearance for THA

Smith & Nephew announces FDA clearance for its CORIOGRAPH platform for total hip arthroplasty.

4 weeks ago · zacks.com

SNN Stock Might Rise Following FDA Nod for AETOS Stemless

Smith & Nephew received FDA 510(k) clearance for a stemless anatomic total shoulder, AETOS Stemless. This represents a significant advancement in shoulder arthroplasty.

1 month ago · proactiveinvestors.co.uk

Smith & Nephew has the potential to pop next year, says leading US investment bank

JP Morgan has doubled down on its "overweight" recommendation for Smith & Nephew PLC (LSE:SN) with its analysts deeming the medical device company undervalued, trading near trough levels, with potenti...

2 months ago · reuters.com

Big investors call for break-up of Smith & Nephew, FT reports

Three major investors are pushing medical device maker Smith & Nephew to consider a break-up of the business, the Financial Times reported on Thursday, citing shareholders.

2 months ago · seekingalpha.com

Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends

Smith & Nephew's Q3 results led to a 13% share price drop due to reduced FY24 guidance, mainly from lower demand in China. Despite short-term challenges, long-term fundamentals remain strong, presenti...

2 months ago · seekingalpha.com

Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript

Smith & Nephew plc (NYSE:SNN ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 AM ET Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Par...

2 months ago · proactiveinvestors.co.uk

Smith+Nephew slashes revenue outlook as China headwinds emerge

British medical equipment manufacturer Smith & Nephew PLC (LSE:SN) slashed its full-year revenue outlook to account for a downturn in demand and pricing pressures in the Chinese market. The FTSE 100-l...

2 months ago · reuters.com

Smith & Nephew slashes annual revenue forecast on weak China

British medical equipment maker Smith & Nephew cut its annual underlying revenue growth forecast on Thursday to 4.5% from the previous outlook range of 5% to 6%, primarily hurt by challenges in its su...

3 months ago · zacks.com

SNN Stock May Gain Following the Co-Marketing Deal With JointVue

Smith & Nephew and JointVue announce a co-marketing agreement for the latter's OrthoSonic 3D Surgery Planning Technology.